Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Board Meeting Intimation for Results & Closure of Trading Window

 FDC Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on August 12, 2016, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2016.Further, in terms of the Code of Conduct adopted by the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window of the Company will remain closed for all...
18-07-2016
Bigul

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016

 FDC Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
15-07-2016

India's pharma market's missing the pep

 The addition of new drugs to the list of medicines under price control and the after effects of the ban on several FDC drugs are reasons for slower growth
14-07-2016
Bigul

Shareholding for the Period Ended June 30, 2016

 FDC Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here
13-07-2016
Bigul

FDC gains after USFDA completes inspection of Waluj unit

 The stock was up 6% to RS 195 on the BSE.
04-07-2016
Bigul

FDC receives two observations from USFDA for Waluj plant

 Drug firm FDC Ltd has received two observations from the US health regulator related to current good manufacturing practice (cGMP) norms for its manufacturing facility situated at Waluj in Maharashtr...
02-07-2016
Bigul

Updates

 FDC Ltd has informed BSE that 1. Inspection of the Company's manufacturing unit situated at Waluj, District- Aurangabad, Maharashtra, by US Food and Drug Administration (US FDA) has been completed on July 01, 2016. The US FDA has made two minor observations for which appropriate steps shall be taken by the Company.The above audit was carried out in relation to cGMP inspection and ANDA filed by the Company for product Dorzolamide Ophthalmic Solution....
02-07-2016
Bigul

Pharma grows 7.7 per cent in May; FDC ban weighs

 MUMBAI: Indian pharmaceutical market grew 7.7 per cent in May compared with 3.5 per cent in April, but the ban on fixed-dose combination (FDC) drugs remains an overhang, says a report. According to data from the AIOCD-AWACS, the market research wing of the All India Organisation of Chemists and Druggists (AIOCD), the pharmaceutical market saw a growth of 7.7 per cent in May as against 3.5 per cent previous month. "We believe the impact of the FDC ban should lessen going ahead as companies launch new combinations," Religare research analyst Praful Bohra said in a report. On the other hand, the non-FDC category grew relatively better at 8.4 per cent in May as against 4.2 per cent in April, he added. The Centre recently banned 344 FDC drugs based on the findings of an expert panel. FDC drugs continued to witness weak growth, mostly in anti-infective and dermatology therapies. Therapy-wise, the anti-diabetic, neurology/CNS and cardiac segments outperformed the pharma market growth by 250-700 bps, while the gastrointestinal and anti-infective segments were laggards, the AIOCD-AWACS report said. Most key players underperformed the pharmaceutical market growth but saw improvement over April, it added. The NLEM and non-NLEM segments in May grew 2.6 per cent and 8.6 per cent, respectively after two months of decline, but were still below the average of 4.7 per cent and 12 per cent posted in the last 12 months. While volumes were sluggish for both NLEM and non-NLEM drugs, NLEM products were also hit by pricing cuts. Indian players and MNCs reported a...
12-06-2016
Bigul

FDC ban hits pharma growth in May; industry not hopeful of a recovery soon

 Segment declined 14.6% in May, when overall industry growth bottomed to 2-year low
11-06-2016
Bigul

India's pharma market dips to a 2-year low in May

 Indian drug makers were more affected by the drop in volumes in FDCs than multinational drug makers in the country, according to PharmaTrack.
10-06-2016
Next Page
Close

Let's Open Free Demat Account